Status:
UNKNOWN
Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer
Lead Sponsor:
CellSight Technologies, Inc.
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
This is a pilot study using \[18F\]F AraG PET imaging to evaluate the immunological response to checkpoint inhibitor therapy (CkIT) in patients with advanced NSCLC tumors at multiple study sites. The ...
Detailed Description
Approximately 50 patients will undergo two research PET/CT scans with \[18F\]F AraG at two time points. Each patient will receive two 5 (+/-10%) mCi doses of \[18F\]F AraG, one for each imaging time p...
Eligibility Criteria
Inclusion
- Patients with a histologically confirmed NSCLC and planned to undergo immunotherapy as monotherapy or as combination therapy with concurrent as treatment for advanced/metastatic disease.
- RECIST measurable disease.
- ECOG performance status of 0, 1 or 2.
- Life expectancy \>/= 6 months at enrollment.
Exclusion
- Serious comorbidities that in the opinion of the investigator/sponsor could compromise protocol objectives.
- Pregnant women or nursing mothers.
- Patients with severe claustrophobia.
Key Trial Info
Start Date :
April 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 15 2024
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT04726215
Start Date
April 15 2021
End Date
October 15 2024
Last Update
September 29 2023
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Palo Alto Veterans Institute of Research
Palo Alto, California, United States, 94304
2
Sutter Cancer Center
Sacramento, California, United States, 95816
3
Stony Brook University
Stony Brook, New York, United States, 11794